The Smith-Kettlewell Eye Research Institute scientist developed Botox for medicinal use.

As Omicron induces a sense of deja vu at the close of the year, we look back at a few key ways in which our understanding has moved forward.

Author Lauren Aguirre finds reasons for optimism in the fight against Alzheimer’s disease.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

The midwestern state has quietly laid the groundwork for a biotech hub.

The East Coast campus of the research institute received shipments of freeze-dried or frozen samples of more than 210,000 microbial strains, which scientists plan to mine for potentially useful natural products.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

In tiny doses, the pufferfish’s tetrodotoxin can be turned into a pain-relieving ion channel blocker.

Compounds in the arachnids’ venom interact with ion channels to both cause and block pain.

If successful, the treatments could alleviate patients’ pain by reducing inflammation.

Decades after their discovery by bioprospectors, amphibian-derived analgesics continue to attract scientific attention.

Studying cone snail venom has yielded novel pain pathways, but the peptides that function as toxins are difficult to translate into drugs.